DS 112
Alternative Names: DS-112Latest Information Update: 21 Oct 2022
At a glance
- Originator North Dakota State University
- Developer DS Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Delta 5 fatty acid desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 Oct 2022 DS 112 is available for licensing as of 20 Oct 2022. https://www.dsbiopharma.com/partnering/
- 20 Oct 2022 Preclinical trials in Solid tumours in Ireland prior to October 2022 (Unspecified) (DS Biopharma pipeline, October 2022)
- 05 Oct 2021 DS Biopharma in-licenses delta 5 desaturase (D5D) inhibitors from North Dakota State University